Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a) data underscore importance of early ...

Core Insights - The article discusses how Johnson & Johnson and Novartis are positioned to navigate patent expirations for key products while maintaining strong financial performance Group 1: Johnson & Johnson - Johnson & Johnson is facing biosimilar competition for its best-selling product Stelara, leading to a significant revenue drop of 42.7% year-over-year to $1.7 billion in Q2 [4] - Despite the decline in Stelara's sales, the company's overall revenue grew by 5.8% year-over-year to $23.7 billion, and it raised both top- and bottom-line guidance for the year [5] - The company has a diversified pharmaceutical portfolio with growth drivers including cancer medicines Darzalex and Erleada, and newer products like Imaavy and TAR-200 [6][7] - Johnson & Johnson is also a leader in the medical device industry, with potential growth from its robotic-assisted surgery system, Ottava [7] - The company has a strong dividend history, having raised payouts for 62 consecutive years, positioning it as a reliable long-term investment [8] Group 2: Novartis - Novartis is preparing for generic competition for its heart failure medication Entresto, which generated $4.6 billion in sales in the first half of the year, with nearly 52% from the U.S. [9] - Despite the impending patent cliff for Entresto, Novartis expects high-single-digit revenue growth for the year, indicating strong overall performance [10] - The company has a diverse portfolio with several blockbuster products, seven of which generated over $1 billion in revenue each in the first half of 2025 [11] - New products like Vanrafia, approved in April, are expected to contribute to future growth, with peak sales estimates of $1.5 billion [12] - Novartis is involved in patent litigation regarding generic versions of Entresto, which could result in financial compensation if it wins [13] - The company has a solid dividend track record, having raised payouts for 28 consecutive years, making it an attractive option for dividend-seeking investors [14]